ÂÜÀòÂÒÂ×

Dr. McGahren brings diverse skill sets and expertise to his investment banking and strategic advisory position from his experience as a biotechnology analyst, consultant, attorney, and physician. Prior to Griffin, Tom was a Senior Director and senior biotech analyst at Merrill Lynch. Forbes ranked him the #1 Drugs Analyst in 2008. Prior to Wall Street, Tom was a litigator at the international law firm of Kaye Scholer from 1993 to 2001, where he represented pharmaceutical and biotechnology companies, particularly in patent, FDA, and corporate matters. Tom received his M.D. from the University of Virginia School of Medicine, a J.D. from the University of Texas School of Law, and a B.A. from Colgate University.